JPRN-jRCT2031220084进行中（未招募）3 期
Phase 3, randomized, double-blind study of the efficacy of TM5614 in combination with tyrosine kinase inhibitors in chronic phase chronic myelogenous leukemia patients
Harigae Hideo0 个研究点目标入组 60 人开始时间: 2022年5月25日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patient aged 18y or older
- •(2) Signed informed consent
- •(3) Patient with Philadelphia chromosome positive chronic phase CML and Major BCR-ABL1 transcript positivity
- •(4) Treatment with imatinib, nilotinib, dasatinib or bosutinib for more than 3 years and less than 6 years
- •(5) No switch between TKIs within the last 12 weeks
- •(6) No dose modification of TKI within the last 12 weeks
- •(7) BCR-ABL(IS) <= 0.1%
- •(8) BCR-ABL(IS) > 0.0032%
- •(9) ECOG PS grade 0 to 2
- •(10) AST and ALT <= 2.5 times the upper limit of the reference value
- •(11) Bilirubin in serum <= 2.5 times the upper limit of the reference value
- •(12) Men and Women of childbearing potential must be using an adequate method of contraception
排除标准
- •(1) Pregnant or lactating women
- •(2) Participation in another clinical trial with any investigative drug within 30 days prior to study enrolment,
- •(3) Prior history of hematopoietic stem cell transplantation (autologous or allogenic)
- •(4) Cardiovascular disease:
- •- Stage II to IV congestive heart failure as determined by the NYHA classification system for heart failure
- •- Myocardial infarction within the previous 6 months
- •- Symptomatic arrhythmias that need treatment
- •(5) Known T315I BCR-ABL kinase domain mutation
- •(6) CML patient not in chronic phase at diagnosis
- •(7) Patients with an active malignancy
- •(8) Known HIV-positivity
- •(9) Patients with bleeding tendency
- •(10) Other patients whom a lead investigator or the patient's primary physician deems are not appropriate for this study
研究者
相似试验
已完成
3 期
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX (ORAL1069)CTRI/2010/091/001027Pfizer Limited960
进行中（未招募）
不适用
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy na?ve adult subjects. - SINGLEHIV-1 infected antiretroviral therapy naive adult subjectsMedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2010-020983-39-ITViiV Healthcare UK Limited800
已完成
3 期
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects (ING114467)HIVHIV110047438NL-OMON38393GlaxoSmithKline10
进行中（未招募）
1 期
GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected adult subjectsHIV-1 infected antiretroviral therapy naive adult subjects.MedDRA version: 14.1Level: LLTClassification code 10008922Term: Chronic infection with HIVSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-020983-39-DKViiV Healthcare UK Limited800
进行中（未招募）
1 期
A phase 3 clinical trial to compare the safety and effectiveness of GSK1349572 and abacavir/lamivudine compared to Atripla over 96 weeks in patients with HIV infection who have not previously received treatment.EUCTR2010-020983-39-GBViiV Healthcare UK Limited844